First-line combination of GELOX followed by radiation therapy for patients with stage IE/IIE ENKTL: An updated analysis with long-term follow-up

Wang,Liang; Wang,Zhi‑Hui; Chen,Xiao‑Qin; Wang,Ke‑Feng; Huang,Hui‑Qiang; Xia,Zhong‑Jun

doi:10.3892/ol.2015.3327

First-line combination of GELOX followed by radiation therapy for patients with stage IE/IIE ENKTL: An updated analysis with long-term follow-up

Authors:
- Liang Wang
- Zhi‑Hui Wang
- Xiao‑Qin Chen
- Ke‑Feng Wang
- Hui‑Qiang Huang
- Zhong‑Jun Xia
View Affiliations

Affiliations: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P.R. China, Department of Medical Oncology, The Fifth Affiliated Hospital, Sun Yat‑sen University, Zhuhai, Guangdong, P.R. China
Published online on: June 5, 2015 https://doi.org/10.3892/ol.2015.3327
Pages: 1036-1040

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In recent years, asparaginase-based chemotherapy regimens have produced excellent short‑term efficacy in patients with extranodal natural killer/T‑cell lymphoma (ENKTL). However, few long‑term outcomes have been reported to date. A phase II clinical trial evaluating the efficacy and safety of a combination of gemcitabine, oxaliplatin and asparaginase (GELOX), followed by radiotherapy (RT) in the treatment of localized ENKTL, was reported by this group in 2012. By the time of the present analysis, detailed information had been collected for all 27 patients in the phase II trial, over an extended follow‑up period. The median follow‑up time was 63.15 months. The 5‑year overall survival and progression‑free survival were 85.0 and 74.0%, respectively. Recurrence within the RT field was observed in three patients, and the planning target‑volume control rate at 5 years was 88.9%. One patient with confirmed lung invasion who did not respond to autologus stem cell transplantation (ASCT) was successfully treated by salvage therapy with lenalidomide monotherapy, and the EBV DNA load in this individual reflected disease progression and treatment response. No clinically significant late toxicities were identified during follow‑up visits. In conclusion, this updated analysis confirmed the long‑term benefit of the GELOX regimen followed by RT, and demonstrated a good safety profile for this treatment. This strategy may be one of the most suitable options for the treatment of early stage ENKTL.

View Figures

View References

1	Li YX, Liu QF, Fang H, Qi SN, Wang H, et al: Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res. 15:2905–2912. 2009. View Article : Google Scholar : PubMed/NCBI
2	Li YX, Wang H, Jin J, Wang WH, Liu QF, et al: Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys. 82:1809–1815. 2012. View Article : Google Scholar : PubMed/NCBI
3	Kohrt H, Lee M and Advani R: Risk stratification in extranodal natural killer/T-cell lymphoma. Expert Rev Anticancer Ther. 10:1395–1405. 2010. View Article : Google Scholar : PubMed/NCBI
4	Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al: Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group study JCOG0211. J Clin Oncol. 27:5594–5600. 2009. View Article : Google Scholar : PubMed/NCBI
5	Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, et al: First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 119:348–355. 2013. View Article : Google Scholar : PubMed/NCBI
6	Baekelandt M, Lehne G, Tropé CG, Szántó I, Pfeiffer P, Gustavssson B and Kristensen GB: Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J Clin Oncol. 19:2983–2993. 2001.PubMed/NCBI
7	Shiraki N, Hamada A, Ohmura T, Tokunaga J, Oyama N and Nakano M: Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine. Biol Pharm Bull. 24:555–557. 2001. View Article : Google Scholar : PubMed/NCBI
8	Wang B, Li XQ, Ma X, Hong X, Lu H and Guo Y: Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol. 83:795–799. 2008. View Article : Google Scholar : PubMed/NCBI
9	Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, et al: Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: The NK-Cell Tumor Study Group study. J Clin Oncol. 29:4410–4416. 2011. View Article : Google Scholar : PubMed/NCBI
10	Martin JK, Sun W, Moraga-A D, Schuster SM and Wylie DE: An investigation into the mechanism of L-asparaginase resistance in L5178Y murine leukemia cells. Amino Acids. 5:51–69. 1993. View Article : Google Scholar : PubMed/NCBI
11	Tse E and Kwong YL: How I treat NK/T-cell lymphomas. Blood. 121:4997–5005. 2013. View Article : Google Scholar : PubMed/NCBI
12	van den Berg H: Asparaginase revisited. Leuk Lymphoma. 52:168–178. 2011. View Article : Google Scholar : PubMed/NCBI
13	Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, et al: Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 117:1834–1839. 2011. View Article : Google Scholar : PubMed/NCBI
14	Chie WC, Yang CH, Hsu C and Yang PC: Quality of life of lung cancer patients: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13. Qual Life Res. 13:257–262. 2004. View Article : Google Scholar : PubMed/NCBI
15	Wang L, Xia ZJ, Huang HQ, et al: Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. Int J Hematol. 96:617–623. 2012. View Article : Google Scholar : PubMed/NCBI
16	Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al: Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: An updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol. 30:4044–4046. 2012. View Article : Google Scholar : PubMed/NCBI
17	Rosenquist R, Davi F and Ghia P: The microenvironment in lymphomas - dissecting the complex crosstalk between tumor cells and ‘by-stander’ cells. Semin Cancer Biol. 24:1–2. 2014. View Article : Google Scholar : PubMed/NCBI
18	Lin ZX, Bai B, Cai QC, et al: High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T- and natural killer cell lymphomas. Med Oncol. 29:3522–3528. 2012. View Article : Google Scholar : PubMed/NCBI
19	Kim HS, Kim KH, Kim KH, Chang MH, Ji SH, et al: Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: Extranodal natural killer/T-cell lymphoma. Leuk Lymphoma. 50:757–763. 2009. View Article : Google Scholar : PubMed/NCBI
20	Suzuki R, Yamaguchi M, Izutsu K, Yamamoto G, Takada K, Harabuchi Y, et al: Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 118:6018–6022. 2011. View Article : Google Scholar : PubMed/NCBI